company background image
ORIN.Y logo

Orion Oyj OTCPK:ORIN.Y Stock Report

Last Price

US$18.00

Market Cap

US$5.2b

7D

-5.3%

1Y

n/a

Updated

26 Mar, 2024

Data

Company Financials +

ORIN.Y Stock Overview

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.

ORIN.Y fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Orion Oyj Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orion Oyj
Historical stock prices
Current Share Price€18.00
52 Week High€24.40
52 Week Low€18.00
Beta0.34
1 Month Change-17.05%
3 Month Change-13.04%
1 Year Changen/a
3 Year Changen/a
5 Year Change-4.76%
Change since IPO8.89%

Recent News & Updates

Recent updates

Shareholder Returns

ORIN.YUS PharmaceuticalsUS Market
7D-5.3%0.2%1.3%
1Yn/a23.1%29.8%

Return vs Industry: Insufficient data to determine how ORIN.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ORIN.Y performed against the US Market.

Price Volatility

Is ORIN.Y's price volatile compared to industry and market?
ORIN.Y volatility
ORIN.Y Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ORIN.Y's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ORIN.Y's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19173,632Liisa Hurmehttps://www.orion.fi

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Orion Oyj Fundamentals Summary

How do Orion Oyj's earnings and revenue compare to its market cap?
ORIN.Y fundamental statistics
Market capUS$5.24b
Earnings (TTM)US$234.81m
Revenue (TTM)US$1.29b

22.1x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORIN.Y income statement (TTM)
Revenue€1.19b
Cost of Revenue€531.90m
Gross Profit€657.80m
Other Expenses€441.00m
Earnings€216.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)1.54
Gross Margin55.29%
Net Profit Margin18.22%
Debt/Equity Ratio21.6%

How did ORIN.Y perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

105%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.